Hemedti to Asharq Al-Awsat: Normalizing Ties with Israel is a Gain for Sudan

Deputy Chairman of the Sovereign Council in Sudan Mohamed Hamdan Dagalo, Asharq Al-Awsat
Deputy Chairman of the Sovereign Council in Sudan Mohamed Hamdan Dagalo, Asharq Al-Awsat
TT

Hemedti to Asharq Al-Awsat: Normalizing Ties with Israel is a Gain for Sudan

Deputy Chairman of the Sovereign Council in Sudan Mohamed Hamdan Dagalo, Asharq Al-Awsat
Deputy Chairman of the Sovereign Council in Sudan Mohamed Hamdan Dagalo, Asharq Al-Awsat

The Deputy Chairman of the Sovereign Council in Sudan, Mohamed Hamdan Dagalo, commonly known as Hemedti, confirmed on Tuesday that the country’s decision to normalize ties with Israel stems from a national conviction.

Hemedti, in an interview with Asharq Al-Awsat, denied the presence of foreign pressure on Khartoum, laying to rest claims that the US had blackmailed the North African state into normalizing relations with Tel Aviv.

Sudan’s historic commitment and stance towards the Palestinian cause does not prohibit its establishment of ties with Israel, Hemedti said, adding that the boycott has been worthless and did not benefit anyone.

“There is no enmity between us and Israel, and no war,” he stated.

“There is no Muslim or Arab army fighting to stand in solidarity with, this means that the boycott is worthless as a weapon,” Hemedti said, emphasizing that Sudan will “reap the fruits of peace and communication with Israel.”

Speaking about the public opinion on normalizing ties with Israel, Hemedti confirmed that 90% of the Sudanese people support the move.

He, however, highlighted that Sudan backs the Palestinian right to a sovereign state.

As for Arab resolutions that press for rejecting Israel on all levels, Hemedti said that “The Three No’s,” established at the 1967 Arab League summit, “did not benefit Sudan in anything.”

That summit is famous for its Khartoum Resolution known as "The Three No's"; No peace with Israel, no recognition of Israel, no negotiations with Israel.

“We are working to reconcile with the whole world and Israel is a part of it,” Hemedti affirmed.

“Sudan has suffered from international isolation for more than 27 years, due to it being listed by the US as a terror sponsoring state,” he explained.

On the war in Darfur, Hemedti said that it constitutes “a revolt against the state.”

He held the state accountable for the crimes committed, but denied it having carried out any ethnic cleansing campaigns.

As the head of the Rapid Support Forces (RSF), an amalgamation of Sudanese paramilitary forces operated by the government, Hemedti said that the RSF will eventually merge with the Sudanese army according to a peace deal between the state and armed factions.



Hevolution CEO Discusses Career in Innovation, Medicine, and Business

Dr. Mehmood Khan, CEO of the Hevolution Foundation
Dr. Mehmood Khan, CEO of the Hevolution Foundation
TT

Hevolution CEO Discusses Career in Innovation, Medicine, and Business

Dr. Mehmood Khan, CEO of the Hevolution Foundation
Dr. Mehmood Khan, CEO of the Hevolution Foundation

Dr. Mehmood Khan, CEO of the Hevolution Foundation, the largest philanthropy organization funding aging medicine in the world, expressed that receiving Saudi citizenship will boost his scientific and practical capabilities.
He said this new status will help him advance his research, especially in addressing aging.
This comes as part of a recent royal decree granting Saudi citizenship to several notable scholars, doctors, researchers, and innovators.
“Our Chairman, his Royal Highness (Crown Prince Mohammed bin Salman), has very high expectations of our work and the impact we need to do; We were created in part because of his vision,” Khan told Asharq Al-Awsat.
“Living up to the expectations and challenges we get faced with is itself exciting, but it is challenging,” revealed Khan, affirming that Hevolution’s team is “up to that task.”
Khan, who has experience in both corporate and medical fields, told Asharq Al-Awsat that his work across academic, public, and private sectors has been a continuous learning process, with each area enhancing the others.
According to the CEO, these industries are interconnected, and combining their strengths often leads to the best solutions.
This insight inspired the Hevolution initiative, which brings together the scientific community, NGOs, pharmaceutical companies, policymakers, academia, biotech firms, CEOs, and others to promote healthy aging.
Khan highlighted the value of integrating insights from different sectors.
Academia provides detailed research, the public sector offers insights on population health and regulations, and the corporate world brings innovation and efficiency, explained Khan, adding that by merging these perspectives, the world can tackle complex health challenges more effectively.
“We’ve been working through, and are now investing, funding and partnering with over 200 scientists around the world, and over 150 different university labs,” said Khan.
Hevolution uses this integrated approach to advance healthy aging.
This initiative embodies my passion for addressing major challenges and offers a significant opportunity to make a global impact.
Khan talked about the first $400 million commitment Hevolution made in the last 23 months, calling it “unprecedented.”
“There has never been a non-profit organization in the world that has gone from not existing to now becoming the largest philanthropy funding aging biology and medicine in the world,” affirmed Khan.
Khan stressed that work at Hevolution not only pushes scientific boundaries but also promotes cross-sector collaboration to improve global health outcomes.
Since Khan’s early days in medical school, he’s been deeply interested in nutrition and population health, which was an unconventional focus back then. This journey set the foundation for his later work in community health.
Khan’s time as an endocrinology faculty member at the Mayo Clinic was crucial. He led programs on diabetes, endocrine diseases, metabolism, and nutrition, which strengthened his expertise in designing disease prevention systems.
In the private sector, Khan took on a key role at Takeda Pharmaceutical as the global head of R&D, which shaped his approach to innovative healthcare solutions.
At PepsiCo, as Chief Scientific Officer, he learned crucial principles of scale, impact, transformation, and tackling global challenges.
As CEO of Hevolution, Khan uses all his professional experience to advance the foundation’s mission of developing health sciences to address age-related diseases.
Khan serves on the boards of Reckitt Benckiser and the Saudi Research, Development, and Innovation Authority (RDIA).
He is the CEO of Life Biosciences, a member of Saudi Arabia’s biotechnology strategy committee, and the chair of the advanced technology visiting committee at the US National Institute of Standards and Technology (NIST).
Khan told Asharq Al-Awsat that he feels honored to have recently become a Saudi citizen by royal decree, while also holding dual US and UK citizenship. This helps him lead Hevolution effectively and work closely with international partners.
Khan commented on his recent Saudi citizenship, saying that in addition to feeling honored to receive Saudi citizenship by royal decree, alongside other distinguished individuals, this recognition is a great privilege.
Being a Saudi citizen, as per Khan, is a significant milestone and acknowledges the progress in his work in aging science and global health. It also strengthens Khan’s commitment to the work at Hevolution.
Khan noted that this new status enhances his ability to build relationships and collaborate within the Kingdom and internationally. It offers a deeper connection with the local community and better opportunities to engage with policymakers and leaders.
He also said that this recognition boosts Hevolution’s global presence and credibility, making the foundation’s collaborations with international scientists and business leaders stronger. It positions Hevolution as a key player in addressing age-related diseases.
Khan emphasized that this honor reflects the hard work and innovation of Hevolution’s entire team.
The CEO said that it was collective efforts that have made this achievement possible.
Khan also said he is excited to engage more deeply with the scientific and medical community in the Kingdom, adding that his new citizenship helps him contribute to Vision 2030 and the national biotechnology strategy, promoting innovation and attracting top global talent.